natgillin/translations-raw huggingface dataset:
All patients considered at risk should be carefully monitored during the initial days of treatment with a special focus on renal function, potassium, and uric acid values. 
Vse bolnike s tveganjem je treba pozorno spremljati med prvimi dnevi zdravljenja s posebno pozornostjo na ledvično delovanje, vrednosti kalija in sečne kisline.
Late onset neutropenia (occurring >28 days after the end of treatment) or prolonged neutropenia (lasting more than 28 days after treatment has been completed/stopped) may occur. 
Pojavi se lahko zapoznela nevtropenija (ki nastopi > 28 dni po koncu zdravljenja) ali dolgotrajna nevtropenija (ki traja več kot 28 dni po dokončanju/prenehanju zdravljenja).
The majority of patients were Caucasian (95%) and male (61%). 
Večina bolnikov je bila belcev (95 %) in 61 % je bilo moških.
At a minimum this should include hepatitis B surface antigen (HBsAg) status and hepatitis B core antibody (HBcAb) status. 
To mora obsegati vsaj določitev stanja površinskega antigena hepatitisa B (HBsAg) in stanja središčnega protitelesa proti hepatitisu B (HBcAb).
This is indicative of target mediated drug disposition (TMDD), where the initial abundance of CD20 cells causes a rapid removal of obinutuzumab from the circulation. 
To kaže na ciljno posredovano odstranjevanje zdravila (target mediated drug disposition - TMDD), pri katerem začetna količina CD20+ celic povzroči hitro odstranjevanje obinutuzumaba iz obtoka.
Therefore, no pharmacokinetic interaction is expected with medicinal products known to be metabolised by these enzyme systems. 
Zato ni pričakovati farmakokinetičnih medsebojnih delovanj z zdravili, ki se presnavljajo s temi encimskimi sistemi.
In patients treated with G+ B, 79.4% received all six treatment cycles compared to 66.7% of patients in the B arm. 
Med bolniki, zdravljenimi z G + B, jih je 79,4 % prejelo vseh šest ciklov zdravljenja; v skupini, ki je prejemala B, je bilo takšnih 66,7 %.
HR (95% CI) 
HR (95-% IZ)
Recovery of B-cells was observed within 12-18 months of follow up in 35% (14 out of 40) of patients without progressive disease and 13% (5 out of 40) with progressive disease. 
Okrevanje celic B so opažali v 12 do 18 mesecih spremljanja pri 35 % (14 od 40) bolnikov brez napredujoče bolezni in pri 13 % (5 od 40) z napredujočo boleznijo.
● a hole in the stomach or intestines (gastrointestinal perforation, especially in cases where the cancer affects the gastrointestinal tubes) 
• luknja v želodcu ali črevesju (predrtje prebavil, še posebej v primerih, ko rak prizadane prebavno cev)
· Full dose (1,000 mg) once every 2 months for up to 2 years as long as your disease does not progress. 
• Celoten odmerek (1000 mg) enkrat na vsaka 2 meseca naslednji 2 leti, dokler vaša bolezen ne napreduje.
A therapy choice for these patients should carefully consider the overall safety profile of Gazyvaro plus chemotherapy and the patient-specific situation. 
Pri izbiri zdravljenja za te bolnike je treba skrbno pretehtati celokupni varnostni profil zdravila Gazyvaro v kombinaciji s kemoterapijo ter specifično situacijo bolnika.
· Store in a refrigerator (2 °C-8 °C). 
• Shranjujte v hladilniku (2-8 °C).
The diagnosis of PML should be considered in any patient presenting with new-onset or changes to pre-existing neurologic manifestations. 
Na diagnozo PML je treba pomisliti pri vsakem bolniku z novonastalimi nevrološkimi spremembami ali spremembi že obstoječih nevroloških stanj.
While fatal haemorrhagic events occurred in less than 1% of patients; none of the fatal adverse events occurred in Cycle 1. 
Hemoragični dogodki s smrtnim izidom so se pojavili pri manj kot 1 % bolnikov, nobeden od neželenih učinkov s smrtnim izidom pa se ni pojavil v 1. ciklu.
· Tell your doctor or nurse if you are pregnant, think you might be pregnant or are planning to have a baby. 
Nosečnost • Zdravniku ali medicinski sestri povejte, če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev.
If toxicity occurs before Cycle 1 Day 8 or Cycle 1 Day 15, requiring delay of treatment, these doses should be given after resolution of toxicity. 
Če se pred 8. dnem 1. cikla ali pred 15. dnem 1. cikla pojavi toksičnost, ki zahteva odlog zdravljenja, se mora te odmerke aplicirati potem, ko toksični učinek izzveni.
· CLL and FL are types of cancer that affect white blood cells called “B-lymphocytes”. 
• KLL in FL sta dve vrsti raka, ki prizadeneta vrsto belih krvnih celic, imenovanih limfociti B.
Gazyvaro is not likely to affect your ability to drive, cycle or use any tools or machines. 
Ni verjetno, da bi zdravilo Gazyvaro vplivalo na vašo sposobnost za vožnjo, kolesarjenje ali uporabo orodij ali strojev.
Antiviral and antifungal prophylaxis should also be considered (see section 4.2). 
Razmisliti je treba tudi o protivirusni in protiglivični profilaksi (glejte poglavje 4.2).
No studies have been performed to establish the carcinogenic potential of obinutuzumab. 
Študij za oceno kancerogenega potenciala obinutuzumaba niso izvedli.
This subgroup comprised 21% (253/1202) of the FL ITT population and experienced 16.3% (40/245) of the PFS events. 
Ta podskupina je predstavljala 21 % (253/1202) populacije folikularnega limfoma z namenom zdraviti in je imela 16,3 % (40/245) primerov PFS.
The median time from initial diagnosis was 3 years and the median number of prior therapies was 2 (range 1 to 10); 44% of patients had received 1 prior therapy and 34% of patients had received 2 prior therapies. 
Mediani čas od prve diagnoze je bil 3 leta in mediano število predhodnih zdravljenj 2 (razpon: od 1 do 10); eno predhodno zdravljenje je prejelo 44 % bolnikov in dve predhodni zdravljenji 34 % bolnikov.
Health-related quality of life assessments, specific to fatigue through treatment period, show no statistically significant difference suggesting that the addition of Gazyvaro to a chlorambucil regimen does not increase the experience of fatigue for patients. 
Ocene kakovosti življenja, specifične za utrujenost med obdobjem zdravljenja, ne kažejo statistično značilne razlike; to kaže, da dodatek zdravila Gazyvaro shemi s klorambucilom bolnikom ne poveča utrujenosti.
No significant difference was observed in the pharmacokinetics of obinutuzumab among patients < 65 years (n=375), patients between 65-75 years (n=265) and patients > 75 years (n=171). 
Farmakokinetika obinutuzumaba se ni bistveno razlikovala med bolniki, starimi < 65 let (n = 375), bolniki, starimi od 65 do 75 let (n = 265), in bolniki, starimi > 75 let (n = 171).
This is because there is no information about its use in these age groups. 
O njegovi uporabi v teh starostnih skupinah namreč ni podatkov.
Therefore patients with a history of cardiac disease should be monitored closely. 
Zato je treba bolnike z anamnezo srčne bolezni natančno nadzirati.
As treatment continues, the impact of this pathway diminishes and the linear clearance pathway predominates. 
Med nadaljevanjem zdravljenja pa se pomen te poti zmanjšuje in prevlada pot linearnega očistka.
The incidence and intensity of adverse reactions reported in these studies did not appear to be dose dependent. 
Incidenca in izrazitost neželenih učinkov, opisanih v teh študijah, po vsem sodeč nista odvisni od odmerka.
However, once the majority of CD20 cells are bound with obinutuzumab, the impact of TMDD on PK is minimised. 
Ko pa je večina CD20+ celic vezana z obinutuzumabom, se vpliv TMDD na farmakokinetiko minimizira.
Obinutuzumab elimination comprises two parallel pathways which describe clearance, a linear clearance pathway and a non-linear clearance pathway which changes as a function of time. 
Obinutuzumab se odstranjuje po dveh vzporednih poteh, ki opisujeta očistek: pot linearnega očistka in pot nelinearnega očistka, ki se spreminja v odvisnosti od časa.
The profile of adverse reactions in patients with FL was consistent with the overall iNHL population in both studies. 
Profil neželenih učinkov pri bolnikih s FL je bil v obeh študijah skladen s celokupno populacijo iNHL.
Gazyvaro will be stored by the healthcare professionals at the hospital or clinic. 
Shranjevanje zdravila Gazyvaro Zdravilo Gazyvaro bodo shranjevali zdravstveni delavci v bolnišnici ali ambulanti.
Dose modifications during treatment (all indications) No dose reductions of Gazyvaro are recommended. 
Prilagoditev odmerka med zdravljenjem (vse indikacije) Zmanjšanja odmerka zdravila Gazyvaro niso priporočljiva.
During the initial treatment, the non-linear time-varying clearance pathway is dominant and is consequently the major clearance pathway. 
Med začetnim zdravljenjem prevladuje pot nelinearnega časovno spremenljivega očistka, ki je posledično glavna pot očistka.
Infusion related reactions 
Reakcije, povezane z infuzijo
Gazyvaro has no or negligible influence on the ability to drive and use machines. 
Zdravilo Gazyvaro ne vpliva ali pa ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
Infusion related reactions can happen during the infusion or up to 24 hours after the infusion. 
Reakcije, povezane z infuzijo, se lahko pojavijo med infundiranjem ali v 24 urah po njem.
The incidence of thrombocytopenia was 14%. 
Incidenca trombocitopenije je bila 14 %.
Fifty-seven percent received bendamustine, 33% received CHOP, and 10% received CVP chemotherapy. 
Sedeminpetdeset % bolnikov je prejelo bendamustin, 33 % kemoterapijo CHOP in 10 % kemoterapijo
Gazyvaro should be prepared by a healthcare professional using aseptic technique. 
Zdravilo Gazyvaro mora pripraviti zdravstveni delavec z uporabo aseptične tehnike.
Based on the FACT-Lym questionnaire and EQ-5D index scale collected during the treatment and during follow-up periods, health-related quality of life was generally maintained in the pivotal study with no meaningful difference between the arms. 
Na podlagi vprašalnika FACT-Lym in indeksne lestvice EQ-5D, uporabljenih med zdravljenjem in obdobjem spremljanja, se je zdravstvena kakovost življenja v ključni študiji na splošno ohranila; med skupinama ni bilo pomembnih razlik.
These may include: 
Med takšnimi so lahko:
Gazyvaro should be administered under the close supervision of an experienced physician and in an environment where full resuscitation facilities are immediately available. 
Dajanje zdravila Gazyvaro mora potekati pod natančnim nadzorom izkušenega zdravnika in v okolju, kjer je takoj na voljo vse potrebno za oživljanje.
Gazyvaro can then be used on its own for up to 2 years as a “maintenance treatment”. 
Zdravilo Gazyvaro lahko do 2 leti uporabljamo samostojno kot vzdrževalno zdravljenje.
Following intravenous administration, the volume of distribution of the central compartment (2.98 L in patients with CLL and 2.97 in patients with iNHL), approximates serum volume, which indicates distribution is largely restricted to plasma and interstitial fluid. 
Po intravenski uporabi je volumen porazdelitve centralnega razdelka (2,98 l pri bolnikih s KLL in 2,97 l pri bolnikih z iNHL) blizu volumna seruma; to kaže, da je porazdelitev v veliki meri omejena na plazmo in intersticijsko tekočino.
The demographic data and baseline characteristics were well balanced between the treatment arms (median age 63 years, the majority were Caucasian [88%] and male [58%]). 
Demografski podatki in izhodiščne značilnosti so bili med zdravljenima skupinama dobro uravnoteženi (mediana starost 63 let, večina je bila belcev [88 %] in moških [58 %]).
The reduction in the risk of disease progression or death seen in the iNHL population is driven by the subset of patients with FL. 
Zmanjšanje tveganja za napredovanje bolezni ali smrt, ki so ga opazili v skupini bolnikov z iNHL, temelji na podskupini bolnikov s FL.
Discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy should also be considered. 
V poštev pride tudi prenehanje ali zmanjšanje morebitne sočasne kemoterapije ali imunosupresivnega zdravljenja.
No specific studies in animals have been performed to evaluate the effect of obinutuzumab on fertility. 
Pri živalih niso izvedli specifičnih študij za oceno vpliva obinutuzumaba na plodnost.
It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue. 
Je specifično usmerjeno na zunajcelično zanko transmembranskega antigena CD20 na površini nemalignih in malignih pre-B in zrelih B-limfocitov, ne pa na krvotvorne matične celice, celice pro-B, zrele plazmatke ali druga normalna tkiva.
Therefore, in order to provide the most comprehensive safety information, the analysis of ADRs presented in the following has been performed on the entire study population (i.e. iNHL). 
vključno s FL. Da bi zagotovili kar najbolj celovite varnostne informacije, je bila analiza neželenih učinkov, predstavljenih v nadaljevanju, izvedena na celotni študijski populaciji (tj. iNHL).
Instructions on the rate of infusion are shown in Tables 4 and 5. 
Navodila glede hitrosti infundiranja so prikazana v preglednicah 4 in 5.
Use of any concomitant therapies which could possibly worsen thrombocytopenia-related events, such as platelet inhibitors and anticoagulants, should also be taken into consideration, especially during the first cycle. 
Upoštevati je treba tudi sočasno uporabo katerih koli zdravil, ki lahko poslabšajo s trombocitopenijo povezane dogodke, na primer zaviralcev trombocitov in antikoagulantov; to je treba še zlasti upoštevati v prvem ciklu.
· On Day 1 of your first cycle, you will be given part of your first Gazyvaro dose of 100 milligrams (mg) very slowly. 
• Prvi dan prvega cikla boste zelo počasi dobili del prvega odmerka zdravila Gazyvaro, ki znaša 100 miligramov (mg).
In the follicular lymphoma studies, a high incidence of infections was observed in all phases of the studies, including follow-up, with the highest incidence seen in the maintenance phase. 
V študijah folikularnega limfoma so v vseh fazah, vključno z obdobjem spremljanja, opazili visoko incidenco okužb; najvišjo incidenco so zaznali pri bolnikih v vzdrževalni fazi.
It should be given as an intravenous infusion through a dedicated line after dilution (see section 6.6). 
Po razredčenju ga je treba dati kot intravensko infuzijo po posebni liniji (glejte poglavje 6.6).
· If you do not have an infusion related reaction following the small part of your first dose, you may be given the rest of your first dose (900 mg) on the same day. 
• Če se vam po infundiranju majhne količine prvega odmerka ne pojavi reakcija, povezana z infuzijo, lahko dobite preostanek prvega odmerka (900 mg) še isti dan.
Store in a refrigerator (2°C-8°C). 
Shranjujte v hladilniku (2-8 °C).
Standard dosing of CHOP and CVP was given. 
Za CHOP in CVP so uporabili standarno odmerjanje.
The median comorbidity score was 8 and 76% of the patients enrolled had a comorbidity score above 6. 
Mediana ocena komorbidnosti je bila 8 in 76 % vključenih bolnikov je imelo oceno komorbidnosti nad 6.
*pre-specified analyses performed on the intent to treat (ITT) population were repeated on the FL population; analysis of double refractory (i.e. unresponsive to or disease progression during or within 6 months of the last dose of an alkylating agent-based regimen) status was exploratory. 
*Vnaprej opredeljene analize, opravljene v populaciji, ki so jo nameravali zdraviti (ITT - intent to treat), so ponovili na populaciji s FL; analiza stanja dvojne refraktarnosti (tj. neodzivnosti ali napredovanja bolezni med ali v 6 mesecih po zadnjem odmerku sheme na podlagi alkilirajočega zdravila) je bila eksplorativna.
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC15 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), monoklonska protitelesa, oznaka ATC: L01XC15
Gazyvaro binds to targets on the surface of the affected “B-lymphocyte” cells and causes them to die. 
Zdravilo Gazyvaro se veže na tarče na površini prizadetih limfocitov B in povzroči, da te celice odmrejo.
Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain magnetic resonance imaging (MRI), and lumbar puncture (cerebrospinal fluid testing for John Cunningham viral DNA). 
Ovrednotenje PML vključuje (a ni omejeno na) posvet z nevrologom, magnetnoresonančno slikanje možganov in lumbalno punkcijo (testiranje cerebrospinalnega likvorja na DNK virusa John Cunningham).
These patients experienced more serious adverse events and adverse events leading to death than those patients < 75 years of age. 
Ti bolniki so imeli več resnih neželenih učinkov in neželenih učinkov, ki so povzročili smrt, kot bolniki, mlajši od 75 let.
Cycle 1: 
1. cikel:
In the pivotal studies in iNHL up to 1% of patients experienced gastrointestinal perforation. 
V ključnih študijah pri iNHL je imelo gastro-intestinalne perforacije do 1 % bolnikov.
If you had recurring or chronic infections before the start of Gazyvaro treatment, tell your doctor about it. 
Če ste pred začetkom zdravljenja z zdravilom Gazyvaro imeli ponavljajoče se ali kronične okužbe, o tem obvestite zdravnika.
Tumour lysis syndrome is a potentially life-threatening complication, caused by chemical changes in the blood due to the breakdown of dying cancer cells (see section 3). 
Sindrom razpada tumorja je lahko življenje ogrožajoč zaplet, ki ga povzročijo kemijske spremembe v krvi zaradi razgradnje odmirajočih rakavih celic (glejte poglavje 3).
The European Medicines Agency has waived the obligation to submit the results of studies with Gazyvaro in all subsets of the paediatric population in CLLand FL (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Gazyvaro za vse podskupine pediatrične populacije pri kronični limfocitni levkemiji in folikularnem limfomu (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The combination of obinutuzumab with chlorambucil, bendamustine, CHOP or CVP may increase the risk of neutropenia (see section 4.4). 
Kombinacija obinutuzumaba s klorambucilom, bendamustinom, CHOP ali CVP lahko poveča tveganje za nevtropenijo (glejte poglavje 4.4).
The planned treatment interval for Gazyvaro should be maintained between doses. 
Med odmerki je treba ohranjati načrtovani terapevtski interval za zdravilo Gazyvaro.
Do not use other diluents such as glucose (5%) solution (see section 6.2). 
Ne uporabljajte drugih raztopin za redčenje, npr. 5-% raztopine glukoze (glejte poglavje 6.2).
NR (25.4,-) 
ND (25,4; -)
Patients who have pre-existing cardiac or pulmonary conditions should be monitored carefully throughout the infusion and the post-infusion period. 
Bolnike z obstoječo boleznijo srca ali pljuč je treba skrbno nadzorovati ves čas infundiranja in v obdobju po njem.
What Gazyvaro is and what it is used for What you need to know before you are given Gazyvaro How Gazyvaro is given 
Kaj je zdravilo Gazyvaro in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Gazyvaro Kako se daje zdravilo Gazyvaro
During maintenance, maintain the original dosing schedule for subsequent doses. 
Med vzdrževanjem za nadaljnje odmerke ohranite originalni razpored odmerjanja.
Patients in the CLL pivotal study BO21004/CLL11 were tested at multiple time-points for anti-therapeutic antibodies (ATA) to Gazyvaro. 
Bolnike s KLL v ključni študiji BO21004/CLL11 so na več časovnih točkah testirali glede protiterapevtskih protiteles (anti-therapeutic antibodies - ATA) proti zdravilu Gazyvaro.
· Tell your doctor or nurse straight away if you have memory loss, trouble speaking, difficulty walking or problems with your eyesight. 
• Zdravniku ali medicinski sestri morate takoj povedati, če se vam poslabša spomin, pojavijo težave z govorom, težave s hojo ali težave z vidom.
Difference in MRD rates, (95% CI) Event free survival 
Razlika v deležih MRD (95-% IZ) Preživetje brez dogodka
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000) in zelo redki (< 1/10.000).
Instructions on the rate of infusion are shown in Tables 4-5. 
Navodila glede hitrosti infundiranja so prikazana v preglednicah 4-5.
Premedication for subsequent infusions and other premedication should be administered as described below. 
Premedikacijo med nadaljnjimi infundiranji in drugo premedikacijo je treba uporabiti, kot je opisano spodaj.
· Tell your doctor or nurse straight away if you get any of the infusion related reactions listed at the start of section 4. 
• Zdravniku ali medicinski sestri morate takoj povedati, če se vam pojavi kakšna reakcija, povezana z infuzijo, navedena na začetku 4. poglavja.
Elderly No dose adjustment is required in elderly patients (see section 5.2). 
Starejši Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
The safety and efficacy of Gazyvaro in patients with impaired hepatic function has not been established. 
Varnost in učinkovitost zdravila Gazyvaro pri bolnikih z okvarjenim delovanjem jeter nista ugotovljeni.
Patients should be closely monitored for thrombocytopenia, especially during the first cycle; regular laboratory tests should be performed until the event resolves, and dose delays should be considered in case of severe or life-threatening thrombocytopenia. 
Bolnike je treba natančno spremljati glede trombocitopenije, zlasti v prvem ciklu; izvajati je treba redne laboratorijske preiskave krvne slike, dokler dogodek ne mine, pri hudi ali življenje ogrožajoči trombocitopeniji pa je treba razmisliti o preložitvi odmerka na kasnejši čas.
Patients with one or more individual organ/system impairment score of 4 as assessed by the CIRS definition, excluding eyes, ears, nose, throat and larynx organ system, were excluded. 
Prav tako so bili izključeni bolniki, ki so imeli oceno okvare enega ali več posameznih organov/organskih sistemov stopnje 4 po definiciji CIRS (izključujoč organske sisteme oči, ušesa, nos, žrelo in grlo).
In the QLQC30 and QLQ-CLL-16 questionnaires conducted during the treatment period, no substantial difference in any of the subscales was observed. 
Ocena z vprašalnikoma QLQC30 in QLQ-CLL-16, opravljena med zdravljenjem, ni na nobeni podlestvici pokazala bistvenih razlik.
Obinutuzumab is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP450), uridine diphosphate glucuronyltransferase (UGT) enzymes and transporters such as P-glycoprotein. 
Obinutuzumab ni substrat, zaviralec ali induktor citokroma P450 (CYP450), encimov uridindifosfatglukuroniltransferaze (UGT) ali prenašalcev, kakršen je P-glikoprotein.
In addition, in vivo, obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC). 
Poleg tega obinutuzumab in vivo posreduje nizko stopnjo od komplementa odvisne citotoksičnosti (complement dependent cytotoxicity - CDC).
Consideration should be given to the need for regular monitoring of blood cell count and for increased risk of infections while patients are B-cell depleted. 
Razmisliti je treba o rednih kontrolah števila krvnih celic in tveganja za okužbe med obdobjem, ko je število celic B zmanjšano.
These events may occur as part of an IRR and can be fatal. 
Ti dogodki se lahko pojavijo kot del reakcij, povezanih z infuzijo, in so lahko smrtni.
For these reasons, comparison of incidence of antibodies to Gazyvaro with the incidence of antibodies to other products may be misleading. 
Zato je lahko primerjava incidence protiteles proti zdravilu Gazyvaro z incidenco protiteles proti drugim zdravilom zavajajoča.
Required amount of Gazyvaro concentrate 
Potrebna količina koncentrata zdravila Gazyvaro
Gazyvaro is for intravenous use. 
Zdravilo Gazyvaro je namenjeno za intravensko uporabo.
The median estimated CrCl was 62 mL/min and 66% of all patients had a CrCl < 70 mL/min. 
Mediana ocenjenega očistka kreatinina je bila 62 ml/min in 66 % vseh bolnikov je imelo očistek kreatinina < 70 ml/min.
· Six 28-day cycles in combination with bendamustine2 or 
• šest 28-dnevnih ciklov v kombinaciji z bendamustinom2 ali
Administer at 25 mg/hr over 4 hours. 
Začnite s hitrostjo 25 mg/uro v 4 urah.